Year Founded
2009
Ownership
Private
Employees
~50
Stage
Preclinical
Modalities
Bispecific T cell engager (BiTE)Bispecific antibodyCAR T cell therapy (CAR-T)

MyriO Tx General Information

Company has multiple preclinical programs with first clinical trial expected to start in 2025 through partnership with Hula Therapeutics at Children's Hospital of Philadelphia

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

MA022-2037
Pre-clinical
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to MyriO Tx's pipeline data

Book a demo

Key Partnerships

Hula Therapeutics, Children's Hospital of Philadelphia

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

MyriO Tx Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view MyriO Tx's complete valuation and funding history, request access »